Risperidone is an antipsychotic commonly used in children and adolescents. The use of risperidone is mostly safe in children, but it can cause some side effects. Few cases of enuresis with risperidone have been reported in the literature so far, some of these cases have been associated with the use of antidepressants or other antipsychotics in combination with risperidone. We present an 8.5-year-old patient with enuresis with risperidone.

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder commencing before the age of 12 years and characterized by developmentally inappropriate inattention, hyperactivity, and/or impulsivity symptoms. Stimulants such as methylphenidate (MPH) are used as first-line therapy for children with ADHD. Psychostimulants may be associated with vascular problems. Raynaud’s phenomenon (RP) is a peripheral vasculopathy potentially associated with connective tissue diseases characterized by recurring reversible vasospasm attacks triggered by cold and emotional stress. Several cases have been published involving RP observed with MPH. The present report discusses a 14-year-old girl with ADHD who experienced RP with the addition of 10 mg modified-release MPH during 27 mg osmotic release (OROS)-MPH therapy, but not during 36 mg OROS-MPH therapy.